Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00618735 · ClinicalTrials.gov registry record · Phase 1
Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT00618735 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 68 participants.
The verdict
NCT00618735, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
The purpose of the study is to see if daily and twice daily administration of BIIB021 is tolerated in patients with advanced solid tumors.
Interventions
- DRUG BIIB021
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00618735
The ClinicalTrials.gov registry entry for NCT00618735 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BIIB021 is the first listed.
NCT00618735 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00618735 about?
NCT00618735 is a clinical study titled "Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors". The purpose of the study is to see if daily and twice daily administration of BIIB021 is tolerated in patients with advanced solid tumors.
What is the current status of trial NCT00618735?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2008-02. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00618735?
The interventions under investigation include: BIIB021 (DRUG).
Who is sponsoring clinical trial NCT00618735?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.